Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study.

What Was Tested

Researchers studied Glucagon in this randomized controlled trial publication.

A recent study in mice points to the gut-derived hormone glucagon-like peptide 2 (GLP-2) as an important regulator of gallbladder motility inducing gallbladder relaxation and refilling.

In this study, the researchers evaluated the effect of exogenous GLP-2 on postprandial gallbladder motility in healthy men.

Who Took Part

PubMed indexes the participants as young adults and adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

Some participants received a placebo instead of Glucagon, giving a reference point.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

Gallbladder volume was assessed by ultrasonography.

What Was Measured

In this study, the researchers evaluated the effect of exogenous GLP-2 on postprandial gallbladder motility in healthy men.

Topics PubMed links to this paper include Gallbladder, Gallbladder Emptying, Glucagon-Like Peptide 2, Healthy Volunteers, Postprandial Period and Ultrasonography.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (Clinical and translational gastroenterology), a journal based in United States.

More context: the Glucagon compound page, all human trials.